Deng Han-Yu, Li Gang, Luo Jun, Wang Zhi-Qiang, Yang Xiao-Yan, Lin Yi-Dan, Liu Lun-Xu
Department of Thoracic Surgery, West China Hospital, Sichuan University, Chengdu 610041, China;; West China School of Medicine, Sichuan University, Chengdu 610041, China.
Information Center, West China Hospital, Sichuan University, Chengdu, 610041, China.
J Thorac Dis. 2016 Dec;8(12):3580-3587. doi: 10.21037/jtd.2016.12.98.
The diagnosis of pulmonary embolism (PE) still remains difficult in clinical practice. MicroRNAs (miRNAs) have been widely investigated as biomarkers for various diseases. However, the diagnostic biomarker value of miRNAs in the diagnosis of PE is unclear. Therefore, we conducted this meta-analysis to establish the diagnostic power of miRNAs for PE diagnosis.
A systematic literature search in PubMed and Embase was conducted to identify relevant studies dated up to July 22, 2016. Data on sensitivity, specificity, positive likelihood ratio (PLR), negative likelihood ratio (NLR), and diagnostic odds ratio (DOR) were pooled from those included studies. Summary receiver operating characteristic (SROC) curves were used to summarize overall diagnostic power of miRNAs for PE diagnosis.
A total of three studies with five types of miRNAs covering 254 participants were included in our meta-analysis. The overall pooled results for sensitivity, specificity, PLR, NLR, and DOR of miRNAs for PE diagnosis were 0.83 [95% confidence intervals (CI): 0.67-0.92], 0.85 (95% CI: 0.72-0.92), 5.4 (95% CI: 2.7-10.9), 0.20 (95% CI: 0.10-0.44), and 26.00 (95% CI: 7.00-101.00), respectively. The area under the SROC curve was 0.90 (95% CI: 0.87-0.92). Even though heterogeneity was observed in the analysis of sensitivity, there was no evidence of publication bias.
MiRNAs could serve as novel non-invasive diagnostic biomarkers of PE with a relatively high diagnostic power. More researches, however, are needed to explore the diagnostic as well as therapeutic values of miRNAs for PE.
在临床实践中，肺栓塞（PE）的诊断仍然困难。微小RNA（miRNA）已被广泛研究作为各种疾病的生物标志物。然而，miRNA在PE诊断中的生物标志物诊断价值尚不清楚。因此，我们进行了这项荟萃分析以确定miRNA对PE诊断的诊断能力。
在PubMed和Embase中进行系统的文献检索，以识别截至2016年7月22日的相关研究。从纳入的研究中汇总敏感性、特异性、阳性似然比（PLR）、阴性似然比（NLR）和诊断比值比（DOR）的数据。采用汇总受试者工作特征（SROC）曲线来总结miRNA对PE诊断的总体诊断能力。
我们的荟萃分析共纳入了三项研究，涉及五种类型的miRNA，涵盖254名参与者。miRNA对PE诊断的敏感性、特异性、PLR、NLR和DOR的总体汇总结果分别为0.83 [95%置信区间（CI）：0.67 - 0.92]、0.85（95% CI：0.72 - 0.92）、5.4（95% CI：2.7 - 10.9）、0.20（95% CI：0.10 - 0.44）和26.00（95% CI：7.00 - 101.00）。SROC曲线下面积为0.90（95% CI：0.87 - 0.92）。尽管在敏感性分析中观察到异质性，但没有发表偏倚的证据。
miRNA可作为PE的新型非侵入性诊断生物标志物，具有相对较高的诊断能力。然而，需要更多的研究来探索miRNA对PE的诊断和治疗价值。
